BILL ANALYSIS                                                                                                                                                                                                    Ó



                                                                            



           ----------------------------------------------------------------- 
          |SENATE RULES COMMITTEE            |                       SB 1438|
          |Office of Senate Floor Analyses   |                              |
          |1020 N Street, Suite 524          |                              |
          |(916) 651-1520         Fax: (916) |                              |
          |327-4478                          |                              |
           ----------------------------------------------------------------- 
           
                                           
                                    THIRD READING


          Bill No:  SB 1438
          Author:   Pavley (D), et al.
          Amended:  5/6/14
          Vote:     21


           SENATE HEALTH COMMITTEE  :  9-0, 4/24/14
          AYES:  Hernandez, Morrell, Beall, De León, DeSaulnier, Evans,  
            Monning, Nielsen, Wolk

           SENATE PUBLIC SAFETY COMMITTEE  :  6-0, 4/29/14
          AYES:  Hancock, Anderson, Knight, Liu, Mitchell, Steinberg
          NO VOTE RECORDED:  De León

           SENATE APPROPRIATIONS COMMITTEE  :  Senate Rule 28.8


           SUBJECT  :    Controlled substances:  opioid antagonists

           SOURCE  :     Author


           DIGEST  :    This bill clarifies that peace officers are included  
          among the persons authorized to receive and distribute opioid  
          antagonists, as specified.  Requires the Emergency Medical  
          Services Authority (EMSA) to establish training and standards,  
          and promulgate regulations, for all prehospital emergency care  
          personnel regarding the use and administration of naloxone  
          hydrochloride (naloxone) and other opioid antagonists.   
          Notwithstanding that requirement, this bill also authorizes a  
          local emergency medical services (EMS) agency to establish  
          training and standards, and promulgate regulations, in lieu of  
          those developed and promulgated by EMSA, as specified.   
                                                                CONTINUED





                                                                    SB 1438
                                                                     Page  
          2

          Clarifies that both of those types of trainings satisfy  
          specified requirements allowing for immunity from criminal and  
          civil liability for administering an opioid antagonist.   
          Additionally, permits the Attorney General (AG), to authorize  
          hospitals and trauma centers to share information with local law  
          enforcement agencies and local EMS agencies.  Limits the data  
          that may be provided by hospitals and trauma centers to the  
          number of overdoses and the substances suspected as the primary  
          cause of the overdoses. 

           ANALYSIS  :    

          Existing law:

           Civil Code
           
          1.Defines "opioid antagonist" as naloxone that is approved by  
            the federal Food and Drug Administration (FDA) for the  
            treatment of an opioid overdose.

          2.Allows a licensed health care provider who is authorized to  
            prescribe naloxone to prescribe and dispense or distribute the  
            medication to a person at risk of an overdose or to a family  
            member, friend, or other person in a position to assist the  
            person at risk of overdose.  Allows a licensed health care  
            provider to issue standing orders for these purposes.

          3.Requires a person who is prescribed or possesses naloxone  
            pursuant to a standing order to receive training by an  
            overdose prevention and treatment training program, as  
            specified.  Specifies that a person who is prescribed naloxone  
            directly from a licensed prescriber, and not through a  
            standing order, is not subject to the training requirement.

          4.Exempts a health care provider who acts with reasonable care  
            in issuing a prescription for naloxone and any person who  
            possesses, distributed, or administers naloxone, with  
            reasonable care, from professional review, civil action, or  
            criminal prosecution.

           Health and Safety Code

           5.Requires EMSA to establish training and standards for all  
            prehospital emergency care personnel, as defined, regarding  







                                                                    SB 1438
                                                                     Page  
          3

            the characteristics and method of assessment and treatment of  
            anaphylactic reactions and the use of epinephrine.  Requires  
            EMSA to promulgate regulations for use by all prehospital  
            emergency care personnel.

          6.Requires the AG to encourage research on the misuse and abuse  
            of controlled substances.  Allows the AG to develop new and  
            improved approaches, techniques, systems, equipment, and  
            devices to strengthen enforcement of the Controlled Substances  
            Act, and to enter into contracts entities, as specified, to  
            conduct demonstrations or special projects that bear directly  
            on the misuse and abuse of controlled substances.

          This bill:

          1.Adds peace officers to the list of people who can receive a  
            prescription for an opioid antagonist for the purpose of  
            assisting a person at risk of an opioid-related overdose.   
            Adds peace officers to the list of people who can receive  
            standing orders for the distribution of an opioid antagonist  
            for this purpose.

          2.Requires EMSA to establish training and standards for all  
            prehospital emergency care personnel on the use and  
            administration of naloxone and other opioid antagonists and to  
            promulgate regulations for this purpose.  Allows EMSA to  
            designate existing training and standards for this purpose.

          3.Permits a local EMS agency, notwithstanding (2) above, to  
            develop its own training and standards, and to promulgate  
            regulations, in lieu of the training and standards and  
            regulations developed by EMSA, for the purpose of considering  
            local need, regarding the use and administration of naloxone  
            and other opioid antagonists by prehospital emergency care  
            personnel under the jurisdiction of that local EMS agency.

          4.Permits the AG to authorize hospitals and trauma centers to  
            share information with local law enforcement and local EMS  
            agencies about controlled substance overdose trends.   
            Specifies that this information is limited to the number of  
            overdoses and the substances suspected as the primary cause of  
            the overdoses and requires the information to be shared in a  
            matter that ensures patient confidentiality.








                                                                    SB 1438
                                                                     Page  
          4

          5.Requires the training, standards, and regulations described in  
            (1) and (2) above to be in line with best practices in the  
            Substance Abuse and Mental Health Services Administration's  
            Opioid Overdose Prevention Toolkit.

          6.Clarifies that the training described in (1) and (2) satisfy  
            the requirements allowing for immunity from criminal and civil  
            liability for administering an opioid antagonist, as  
            specified.

           


          Background
           
           Deaths related to opioid overdose  .  According to the Centers for  
          Disease Control and Prevention (CDC), there were nearly 37,000  
          drug overdose deaths in the United States in 2008 and  
          approximately 4,300 drug poisoning deaths in California.   
          Counties experiencing the highest numbers of overdose deaths  
          were Alameda, Fresno, Kern, Los Angeles, Orange, Riverside,  
          Sacramento, San Bernardino, San Diego, San Francisco, and Santa  
          Clara.  In 2009, 28,754 (91%) of all unintentional poisoning  
          deaths were caused most commonly by prescription opioids, which  
          include such drugs as methadone, hydrocodone (Vicodin), and  
          oxycodone (Oxycontin), followed by cocaine and heroin.

           Naloxone  .  According to the FDA, naloxone, which is not a  
          controlled substance, rapidly reverses the effects of opioid  
          overdose and is the standard treatment for overdose, which is  
          characterized by decreased breathing or heart rate or loss of  
          consciousness.  The National Institute on Drug Abuse's Internet  
          Web site states that, as of March 2014, 17 states have passed  
          laws that allow for wider prescribing of naloxone to those who  
          can help prevent overdoses, such as family and friends of drug  
          addicts and a wide array of emergency personnel, like police and  
          firefighters.  Some overdose prevention programs use syringes  
          fitted with atomizers to enable to medication to be sprayed into  
          the nose.

          In April 2014, the FDA announced the approval of a new hand-held  
          auto-injector to reverse opioid overdose.  The medication is  
          injected into the muscle or under the skin.  The new device  
          provides verbal instruction, similar to an automated  







                                                                    SB 1438
                                                                     Page  
          5

          defibrillator.  The FDA granted a fast-track designation, which  
          is designed to facilitate development and to expedite the review  
          of drugs to treat serious conditions and fill unmet medical  
          need, according to the FDA's Internet Web site.

           Results of naloxone distribution and administration  .  A 2012 CDC  
          report on programs known to distribute naloxone documented the  
          reversal of more than 10,000 heroin overdoses.  The programs  
          provided opioid overdose education and naloxone to drug users  
          and to those who might be present during a drug overdose in  
          order to help reduce overdose deaths.  However, of the 48  
          programs that responded, nearly half reported problems in  
          obtaining naloxone related to cost and a shortage of supply.

          According to the Drug Policy Alliance's (DPA's) Internet Web  
          site, naloxone has been safely and effectively used for more  
          than 40 years in ambulances and emergency rooms across the  
          country.  Naloxone has no potential for abuse and side effects  
          are rare.  DPA also cites ongoing research showing that  
          expanding access to naloxone does not promote increased drug use  
          or risk-taking behavior that results in unintended overdoses.

           Prior Legislation

           AB 635 (Ammiano, Chapter 707, Statutes of 2013) expanded the  
          program in AB 2145 (Ammiano, Chapter 545, Statutes of 2010)  
          statewide; deleted the sunset date and the reporting  
          requirements; and modified the limited liability provisions for  
          both licensed health care professionals who prescribe, dispense,  
          or distribute naloxone and unlicensed persons who act with  
          reasonable care to administer naloxone to a person who is  
          experiencing or is suspected to be experiencing an overdose.

          AB 2145 (Ammiano) extended the sunset date of the seven-county  
          pilot program established under SB 767 (Ridley-Thomas, Chapter  
          477, Statutes of 2007) to January 1, 2016; extended to January  
          1, 2015, the deadline for the requirement of local health  
          jurisdictions operating an overdose prevention program to  
          report, as specified, to the Senate and Assembly Committees on  
          Judiciary; and added immunity for unlicensed trained people who  
          administer an opioid antidote in emergency situations during  
          which they believe that a person is experiencing a drug  
          overdose.








                                                                    SB 1438
                                                                     Page  
          6

          SB 767 (Ridley-Thomas) established a seven-county pilot program  
          until January 1, 2010, in which licensed health care providers  
          were given immunity from civil liability or criminal prosecution  
          when they prescribed naloxone to a person in connection with an  
          opioid overdose prevention and training program on how to  
          recognize and respond to an opiate overdose.  Required local  
          health jurisdictions operating an overdose prevention program to  
          report, as specified, to the Senate and Assembly Committees on  
          Judiciary by January 1, 2010.

          SB 1695 (Escutia, Chapter 678, Statutes of 2002) authorized  
          counties to establish training and certification programs to  
          permit an EMT-I to administer naloxone by means other than  
          intravenous injection if he/she has completed training and  
          passed a test.  Required EMSA to develop guidelines relating to  
          the county certification programs.

          SB 1134 (Escutia, 2001) contained, among other things, the  
          provisions in SB 1695 above.  SB 1134 was vetoed by Governor  
          Davis who cited cost reasons related to provisions in the bill  
          that required grants for drug overdose prevention programs.

          SB 851 (Oller, 2001) required the EMSA to develop and implement  
          procedures and protocols to permit EMT-I's in Sierra County to  
          obtain training and certification to safely administer emergency  
          medical procedures, including naloxone, that are outside of  
          their scope of practice.  This bill died in the Senate Health  
          and Human Services Committee.

           FISCAL EFFECT  :    Appropriation:  No   Fiscal Com.:  Yes    
          Local:  No

           SUPPORT  :   (Verified  5/19/14)

          California Chapter of the American College of Emergency  
          Physicians
          California Pharmacists Association
          California State Sheriffs' Association
          Drug Policy Alliance
          Emergency Medical Services Administrators' Association of  
          California

           ARGUMENTS IN SUPPORT  :    The DPA writes that this bill is an  
          urgently needed measure to allow first responders to administer  







                                                                    SB 1438
                                                                     Page  
          7

          opiate overdose reversal medication, naloxone, to a person at  
          risk of a fatal overdose.  Naloxone has been extensively  
          researched and widely used by a number of health care entities  
          for decades and several states have already expanded usage to  
          peace officers with no reports of negative outcomes for patient  
          safety.  DPA believes this bill is part of a comprehensive  
          strategy to combat the epidemic of opiate overdoses in  
          California.


          JL:e  5/20/14   Senate Floor Analyses 

                           SUPPORT/OPPOSITION:  SEE ABOVE

                                   ****  END  ****